Archived Comments for:
Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
Coen Stehouwer, Maastricht University Medical Centre
7 May 2015
Erratum
After publication of [1], it has come to our attention that the samples used for the MMPs and TIMP-1 measurements were serum samples instead of plasma samples. Therefore,
1. Plasma levels of MMPs and TIMP-1 in the title, abstract, methods, results and discussion section should read serum levels; and
2. In the discussion section, the following paragraph: “We did not find a significant association of plasma MMPs or TIMP-1 levels with non-proliferative retinopathy. This is in contrast with the results of the study of Jacqueminet et al [10], in which increased serum MMP-9 levels were shown in patients with type 1 diabetes with minimal to moderate retinopathy (n=14) compared to diabetic patients without retinopathy and non-diabetic controls. Possibly the serum measurement does not truly reflect the circulating concentration of MMPs and TIMPs compared to the plasma measurement [35]” should read “We did not find a significant association of serum MMPs or TIMP-1 levels with non-proliferative retinopathy. This is in contrast with the results of the study of Jacqueminet et al [10], in which increased serum MMP-9 levels were shown in patients with type 1 diabetes with minimal to moderate retinopathy (n=14) compared to diabetic patients without retinopathy and non-diabetic controls.”
We apologize for any inconveniece.
Stijn A. Peeters1,2, Lian Engelen1, Jacqueline Buijs2, Nish Chaturvedi3, John H. Fuller4, Casper G. Schalkwijk1, Coen D. Stehouwer1*; EURODIAB Prospective Complications Study Group
Author details
1Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands. 2Department of Internal Medicine, Atrium Medical Centre, Heerlen, the Netherlands. 3Institute of Cardiovascular Sciences, University College London, London, U.K. 4Department of Epidemiology and Public Health, University College London, London, U.K.
Reference:
1. Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol 2015, 14:31.
Competing interests
The authors declare that they have no competing interests.
Cardiovascular Diabetology
Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
7 May 2015
Erratum
After publication of [1], it has come to our attention that the samples used for the MMPs and TIMP-1 measurements were serum samples instead of plasma samples. Therefore,
1. Plasma levels of MMPs and TIMP-1 in the title, abstract, methods, results and discussion section should read serum levels; and
2. In the discussion section, the following paragraph: “We did not find a significant association of plasma MMPs or TIMP-1 levels with non-proliferative retinopathy. This is in contrast with the results of the study of Jacqueminet et al [10], in which increased serum MMP-9 levels were shown in patients with type 1 diabetes with minimal to moderate retinopathy (n=14) compared to diabetic patients without retinopathy and non-diabetic controls. Possibly the serum measurement does not truly reflect the circulating concentration of MMPs and TIMPs compared to the plasma measurement [35]” should read “We did not find a significant association of serum MMPs or TIMP-1 levels with non-proliferative retinopathy. This is in contrast with the results of the study of Jacqueminet et al [10], in which increased serum MMP-9 levels were shown in patients with type 1 diabetes with minimal to moderate retinopathy (n=14) compared to diabetic patients without retinopathy and non-diabetic controls.”
We apologize for any inconveniece.
Stijn A. Peeters1,2, Lian Engelen1, Jacqueline Buijs2, Nish Chaturvedi3, John H. Fuller4, Casper G. Schalkwijk1, Coen D. Stehouwer1*; EURODIAB Prospective Complications Study Group
Author details
1Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands. 2Department of Internal Medicine, Atrium Medical Centre, Heerlen, the Netherlands. 3Institute of Cardiovascular Sciences, University College London, London, U.K. 4Department of Epidemiology and Public Health, University College London, London, U.K.
Reference:
1. Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol 2015, 14:31.
Competing interests
The authors declare that they have no competing interests.